Close Menu

NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its first quarter revenues rose 9 percent thanks in large part to a 39 percent increase in system revenues and record revenues from assays and royalties.

For the three months ended March 31, the molecular diagnostics firm reported revenues of $63.0 million, up from $57.7 million a year ago, and beating the consensus Wall Street estimate of $61.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.

The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.

Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.

In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.